Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

Archive ouverte

Bergmeijer, Thomas | Reny, Jean-Luc | Pakyz, Ruth | Gong, Li | Lewis, Joshua | Kim, Eun-Young | Aradi, Daniel | Fernandez-Cadenas, Israel | Horenstein, Richard | Lee, Ming Ta Michael | Whaley, Ryan | Montaner, Joan | Gensini, Gian Franco | Cleator, John | Chang, Kiyuk | Holmvang, Lene | Hochholzer, Willibald | Roden, Dan | Winter, Stefan | Altman, Russ | Alexopoulos, Dimitrios | Kim, Ho-Sook | Déry, Jean-Pierre | Gawaz, Meinrad | Bliden, Kevin | Valgimigli, Marco | Marcucci, Rossella | Campo, Gianluca | Schaeffeler, Elke | Dridi, Nadia | Wen, Ming-Shien | Shin, Jae Gook | Simon, Tabassome | Fontana, Pierre | Giusti, Betti | Geisler, Tobias | Kubo, Michiaki | Trenk, Dietmar | Siller-Matula, Jolanta | ten Berg, Jurriën | Gurbel, Paul | Hulot, Jean-Sebastien | Mitchell, Braxton | Schwab, Matthias | Ritchie, Marylyn Deriggi | Klein, Teri | Shuldiner, Alan

Edité par CCSD ; Elsevier -

International audience. The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and clinical response.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion